TAB008 + paclitaxel + carboplatin

TAB008 + paclitaxel + carboplatin is a **triple-drug combination regimen** used in oncology, typically for the treatment of advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC). - **TAB008** is a biosimilar of bevacizumab (Avastin), a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), used to inhibit angiogenesis in tumors. - **Paclitaxel** is a small molecule antineoplastic agent that stabilizes microtubules, inhibiting cell division. - **Carboplatin** is a platinum-based small molecule chemotherapeutic that crosslinks DNA, leading to apoptosis. In clinical studies, this combination is administered as TAB008 (or Avastin) 15 mg/kg intravenously plus paclitaxel and carboplatin every 3 weeks for up to 4–6 cycles, followed by maintenance TAB008. The combination was shown to have efficacy, safety, and pharmacokinetic profiles similar to standard bevacizumab plus chemotherapy regimens in phase III studies in lung cancer. The principal developer for TAB008 is TOT BIOPHARM. Paclitaxel and carboplatin are generic agents produced by multiple manufacturers. The regimen is not a single commercial product but a protocolized combination[7].

Other names

paclitaxel and carboplatinPCCaCARBOPLATIN-TAXOL